RxDoctor Payments Data

Meghan Daversa

Physician Assistant · Mineola, NYNPI 1952554164

Payments from drug & device makers

$3,835in general payments, 2019–2025

Across 96 payments — averaging $39.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Aurinia Pharma U.S., Inc.$362
  • Amgen$126

What the payments were for

  • Food & beverage$3,835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie92$3,348
Aurinia Pharma U.S., Inc.3$362
Amgen1$126

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,835 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$84,463
Medicare patients
85
Services billed
3,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$488,454
Enbrel SureclickEtanercept21$234,943
OtezlaApremilast21$121,264
Teriparatide14$62,415
Hydroxychloroquine Sulfate130$4,287
Leflunomide52$4,256
Cevimeline Hcl13$3,900
MethotrexateMethotrexate Sodium103$3,644
Pregabalin44$1,649
Celecoxib26$1,452
Prednisone172$1,384
Colchicine13$824
Sulfasalazine16$627
Leucovorin Calcium12$425
Folic Acid21$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$126$121,26421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →